Navigation Links
Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
Date:10/31/2013

EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among surveyed endocrinologists and primary care physicians (PCPs), Janssen Pharmaceuticals' Invokana captures a small percentage of type 2 diabetes patient share, with significant increases expected six months from now. Currently, a majority of type 2 diabetes patients are using metformin (excluding fixed-dose combinations) and one-third of patients are treated with long-acting insulins such as Sanofi's Lantus or Novo Nordisk's Levemir.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO

The TreatmentTrends®: Type 2 Diabetes (U.S.) 2013 report also finds that, within the GLP-1 drug class, Novo Nordisk's Victoza is the patient share leader, followed by Bristol-Myers Squibb/AstraZeneca's Byetta/Bydureon (if these products are considered independently).

The report examines five products in development for the treatment of type 2 diabetes—Bristol-Myers Squibb/AstraZeneca's dapagliflozin, GlaxoSmithKline's albiglutide, Eli Lilly's dulaglutide, Novo Nordisk's Tresiba and Takeda's fasiglifam. After reviewing a product profile, surveyed endocrinologists indicated a higher mean interest level for the long-acting insulin Tresiba versus the SGLT-2 inhibitor dapagliflozin.

"The report focuses on physician perception of type 2 diabetes product satisfaction, attribute importance, product performance and sales representative frequency and performance," said BioTrends Research Group Director Rob Dubman. "For example, the study found that at least 40 percent of surveyed physicians have seen a sales representative in the past m
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
2. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
3. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
4. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
5. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
6. Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies
7. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
8. A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
9. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
10. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
11. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Wash. , Dec. 19, 2014  Advanced ... stage development company engaged primarily in the development ... and therapeutic applications, today announced that a Life ... has been awarded for which AMIC is the ... State University (WSU) for the proposal titled "Optimized ...
(Date:12/19/2014)... 2014 In today,s rapidly changing, highly ... tools are essential for survival. The world is ... desires, preferences, and unmet needs are evolving rapidly. ... across all industries are continually searching for innovative ... adoption of new market research techniques like mobile ...
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between ... hearing health was forgotten. But Audicus , a ... hear better this new year. Hearing loss ... the aging population, though it is often unaddressed. Forty-eight ... four has a hearing aid, mainly due to price. ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Audicus Will Help People Resolve to Hear Better in 2015 2
... 20 Valor Medical, an emerging medical,device company in ... of Neucrylate AN for treatment of cerebral aneurysms was ... The treatment was under the,guidance of a clinical protocol ... Dr. Pakbaz stated that the patient,s aneurysm was ...
... Ages, ALEXANDRIA, Va., March 19 A ... 18, 2008) reports that pelvic,floor muscle training, in ... incontinence in women. According to the American,Physical Therapy ... physical therapist can help patients manage, if not,alleviate, ...
Cached Medicine Technology:New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women 2New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women 3New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women 4
(Date:12/20/2014)... San Francisco, CA (PRWEB) December 20, 2014 ... a Social Innovation company just launched first birthday focused ... the services, “MERRY BIRTHDAY MESSAGE” launched in both US ... , MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , ... launching for everyone’s birthday around the world. , Features, ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Developers of ... release of a new plugin for Final Cut Pro ... , “TranSlice Volume 5 allows users to create hand ... it.” Said Christina Austin, CEO of Pixel Film Studios. ... of professionalism while maintaining an easy to use interface.” ...
(Date:12/20/2014)... Parker & Sons, Inc. a focused and ... in contractor services announces reaching a milestone by providing ... of Arizona. Parker and Sons is comprised of a ... make customer service the number one priority. The company ... with one service vehicle and has since grown to ...
(Date:12/19/2014)... 20, 2014 It’s very easy to become ... that is put to the wayside until Christmas and the ... that travel “itch” and that burning desire to just escape ... on their journey to Telluride with a no-fuss, affordable package. ... and from the resort, and ensure that all accommodations are ...
(Date:12/19/2014)... FL (PRWEB) December 19, 2014 ... Revitalizing Bedsheets are now available. Celliant, the world’s ... both sheets and pillowcases. , There are a ... proven additional circulation, increased oxygenation and balanced body ... faster healing and pain relief; enhanced athletic performance; ...
Breaking Medicine News(10 mins):Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2
... Aero Financial, Inc, a strategic advisory and finance & ... been retained as a strategic consulting partner by Only ... information and nutrition products.Pursuant to the consulting agreement, Aero ... of the company,s growth plans, including:, ...
... Industry Professionals Available for Comment on Health Reform under Obama ... ... LLP today published a brief entitled 10 Minutes on Health ... alter the employer-based insurance system, the advantages of universal healthcare ...
... Why? , ... (PRWEB) January 22, 2009 -- Web 2.0, Health 2.0, ... are appearing more and more in the healthcare space and many hospital ... their marketing plans as another way to increase market share and build ...
... SEATTLE, Jan. 22 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... by,Esmaeli, et al. online on January 15, 2009 in ... agent Zevalin (ibritumomab,tiuxetan) in a front-line setting for patients ... involved the conjunctiva or orbit,produced a complete response rate ...
... HealthSystem,Consortium (UHC) today announced that after a competitive ... measurement services to Avatar,International and Press Ganey Associates, ... with options to extend. The agreements are effective ... Under the agreements, Avatar and Press Ganey ...
... Gen. Eric K. Shinseki took the oath of office ... assuming the leadership of the Department of Veterans Affairs ... am addressing from my first day in office is ... century organization focused on the Nation,s Veterans as its ...
Cached Medicine News:Health News:Aero Financial Retained as Strategic Consultant by Only Natures Finest(TM) 2Health News:Media Alert: PricewaterhouseCoopers Publishes Brief on the Impact of Government Health Reform on U.S. Employers 2Health News:Media Alert: PricewaterhouseCoopers Publishes Brief on the Impact of Government Health Reform on U.S. Employers 3Health News:Media Alert: PricewaterhouseCoopers Publishes Brief on the Impact of Government Health Reform on U.S. Employers 4Health News:Hope is Not a Strategy: Neither is Web 2.0 for a Hospital 2Health News:Hope is Not a Strategy: Neither is Web 2.0 for a Hospital 3Health News:Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma 2Health News:Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma 3Health News:Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma 4Health News:University HealthSystem Consortium Announces Dual Award for Patient Satisfaction Measurement Services 2Health News:Shinseki Sworn In, Vows 21st Century Service to Veterans 2
4 mm blade. Flat handle....
9 mm button end blade. 15 mm long backcutting blade. Angled at 45 degrees. Flat handle. Designated most popular model or size....
10 mm blade, angled left. Flat handle....
4 mm blade. Bayonet. Flat handle....
Medicine Products: